Examining blood clotting in autoimmune skin diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the coagulation and fibrinolysis profiles in patients with autoimmune skin diseases. Blood samples will be collected from individuals with both active and well-controlled immune-mediated skin conditions, as well as from a control group of dermatology outpatients without such diseases. The study will compare coagulation and inflammatory markers between these groups to better understand the implications of coagulation profiles in autoimmune skin diseases. The findings may pave the way for future research on the clinical relevance of these profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis
2. For control group: no diagnosis of immune-mediated skin
3. For study group: receiving care from one or more of the Principal or Secondary Investigators

Exclusion Criteria:

1. Unfit to provide consent
2. P2Y12 inhibitor use in the past 4 weeks
3. History of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies)
4. Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study
5. Other autoimmune diseases not in remission defined as flare in the last 12 weeks
6. If patient is unable to provide detailed history and if we do not have sufficient history on record.
7. Less than 19 years of age

Where it's running

• University of Nebraska Medical Center
  Omaha, Nebraska, United States Recruiting

Study contacts

• Principal investigator: Erin X Barrett, MD — University of Nebraska
• Study coordinator: Megan E Wackel, MS
• Email: megan.wackel@unmc.edu
• Phone: 402-559-3825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarkers that predict how skin-disease treatments will work

  Researchers are testing blood and skin markers to see if they can forecast which patients with inflammatory skin diseases will respond to systemic treatments over a year.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06599411

• Collection of biological samples from patients with autoimmune skin diseases

  This study is collecting blood and other samples from people with autoimmune skin diseases to see if it can find new ways to diagnose and treat these conditions.

  Recruiting University Hospital, Toulouse · Toulouse · NCT06387654

• Collection of samples and data for severe drug reactions

  This study is collecting samples and information from patients with severe skin reactions to better understand what causes these reactions and how to improve treatment and prevention.

  Recruiting Assistance Publique - Hôpitaux de Paris · Créteil · NCT03659227

• Evaluating CM336 for treating autoimmune bullous disease in adults

  This study is testing a new treatment called CM336 to see if it can help adults with moderate to severe autoimmune bullous disease feel better.

  Recruiting Phase 2 Shandong First Medical University · Jinan · NCT06900010

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.